Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia

Cancer cell cycle inhibitor is Lin BioScience's second candidate to receive Orphan Drug Designation SAN DIEGO, April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Lin BioScience, a drug development company targeting unmet clinical needs in onco... Biopharmaceuticals, Oncology, FDA Lin BioScience, LBS-007, acute lymphoblastic leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancer Science,Volume 0, Issue ja, -Not available-.
Source: Cancer Science - Category: Cancer & Oncology Authors: Source Type: research
AbstractPurposeMethotrexate polyglutamates (MTXpg) facilitate incorporation of thioguanine nucleotides into DNA (DNA-TG, the primary cytotoxic thiopurine metabolite and outcome determinant in MTX/6-mercaptopurine treatment of childhood ALL). We hypothesized that mapping erythrocyte levels of MTXpg with 1 –6 glutamates and their associations with DNA-TG formation would facilitate future guidelines for maintenance therapy dosing.Methods and resultsSummed MTX with 1 –6 glutamates resolved by LCMS [median (interquartile): 5.47 (3.58–7.69) nmol/mmol hemoglobin] was in agreement with total MTX by radio ligand a...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Publication date: December 2018Source: Cancer Epidemiology, Volume 57Author(s): Areesha Alam, Archana KumarAbstractBackgroundTreatment refusal or abandonment are among the major causes of the survival gap between developed and developing countries.MethodsThis retrospective observational study analyzed records of children aged
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Abstract Tisagenlecleucel (Kymriah, Novartis Pharmaceuticals, East Hanover, NJ) is a CD19-directed genetically-modified autologous T-cell immunotherapy. On August 30, 2017, the U.S. Food and Drug Administration approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Approval was based on the complete remission (CR) rate, durability of CR and minimal residual disease (MRD)
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
l D Abstract OX40 and its ligand are members of the TNF/TNF receptor superfamily, which includes various molecules influencing cellular signaling and function of both tumor and immune cells. The ability of OX40 to promote proliferation and differentiation of activated T cells fueled present attempts to modulate this immune checkpoint to reinforce antitumor immunity. While we recently found evidence for the involvement of OX40 in pathophysiology of acute myeloid leukemia including natural killer (NK) cell immunosurveillance, less is known on its role in acute lymphoblastic leukemia (ALL). In the present study, OX40...
Source: Neoplasia - Category: Cancer & Oncology Authors: Tags: Neoplasia Source Type: research
The RNA-binding protein Musashi 2 (MSI2) has emerged as an important regulator in cancer initiation, progression, and drug resistance. Translocations and deregulation of the MSI2 gene are diagnostic of certain cancers, including chronic myeloid leukemia (CML) with translocation t(7;17), acute myeloid leukemia (AML) with translocation t(10;17), and some cases of B-precursor acute lymphoblastic leukemia (pB-ALL). To better understand the function of MSI2 in leukemia, the mRNA targets that are bound and regulated by MSI2 and their MSI2-binding motifs need to be identified. To this end, using photoactivatable ribonucleoside cr...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Gene Regulation Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Marketing | Pharmaceuticals